An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
- 1 May 2001
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 120 (6) , 1330-1338
- https://doi.org/10.1053/gast.2001.24042
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and SafetyInflammatory Bowel Diseases, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Tumour necrosis factor and Crohn's disease.Gut, 1997
- Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's diseaseThe Lancet, 1997
- Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut, 1993
- Humanized antibodiesImmunology Today, 1993
- Tumour necrosis factor alpha in stool as a marker of intestinal inflammationThe Lancet, 1992
- Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.Gut, 1991